AstraZeneca(US:AZN) 2 1 Shi Ji Jing Ji Bao Dao·2025-11-07 15:09Core Viewpoint - The 8th China International Import Expo (CIIE) showcases global high-quality resources, with the medical devices and healthcare section being a major highlight, particularly featuring AstraZeneca's commitment to innovation and collaboration in the Chinese pharmaceutical market [2][4]. AstraZeneca's Role and Contributions - AstraZeneca has participated in all eight editions of the CIIE, presenting 20 innovative products that address various medical needs, including respiratory, renal, digestive, rare diseases, autoimmune conditions, and multiple cancers [2]. - The company emphasizes its role in facilitating Chinese innovation on a global scale, hosting a roundtable forum during the expo to discuss key drivers of pharmaceutical innovation in China [2][4]. Evolution of Collaboration Models - AstraZeneca's collaboration in China has evolved from simple licensing agreements to a comprehensive ecosystem of partnerships, focusing on research collaboration, strategic investments, and AI empowerment [5][6]. - The partnership with Heptares Therapeutics exemplifies this evolution, transitioning from single molecule licensing to a deep strategic collaboration covering multiple targets and projects [5][6]. Focus on Early Research and AI Integration - AstraZeneca's strategy in China prioritizes early-stage research and clinical development, leveraging China's unique advantages in research efficiency and diverse patient demographics [8][9]. - The integration of AI technology is revolutionizing research efficiency, with AI applications expanding from drug discovery to the entire clinical development process [9][10]. Impact on Global Pharmaceutical Landscape - AstraZeneca's collaborations with Chinese pharmaceutical companies are elevating their status from participants to co-creators in the global value chain, enhancing the quality of healthcare solutions available to patients worldwide [11].